Encouraging preclinical findings suggested that the co-treatment of E/LPN-KL and miR125/SLN-KL given to SAS-bearing mice reduced blood glucose and cholesterol levels (Figure 7a,b), indicating that E/LPN-KL and miR125/SLN-KL might modulate the pathways associated with tumor lipid and glucose metabolism and, consequently, disturb tumor progression and growth. Here, KL is linked to neoplasm.